Akebia Therapeutics Inc. (NASDAQ: AKBA) kicked off on Friday, down -2.16% from the previous trading day, before settling in for the closing price of $1.39. Over the past 52 weeks, AKBA has traded in a range of $0.59-$2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 5.16%. While this was happening, its average annual earnings per share was recorded 0.32%. With a float of $186.68 million, this company’s outstanding shares have now reached $194.58 million.
Let’s determine the extent of company efficiency that accounts for 167 employees.
Akebia Therapeutics Inc. (AKBA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Akebia Therapeutics Inc. is 10.84%, while institutional ownership is 18.46%. The most recent insider transaction that took place on Feb 29 ’24, was worth 73,581. In this transaction CEO and President of this company sold 46,570 shares at a rate of $1.58, taking the stock ownership to the 2,044,580 shares. Before that another transaction happened on Feb 29 ’24, when Company’s SVP, Chief Operating Officer sold 8,661 for $1.58, making the entire transaction worth $13,684. This insider now owns 706,932 shares in total.
Akebia Therapeutics Inc. (AKBA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 40.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.32% per share during the next fiscal year.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Trading Performance Indicators
Take a look at Akebia Therapeutics Inc.’s (AKBA) current performance indicators. Last quarter, stock had a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc. (AKBA)
Looking closely at Akebia Therapeutics Inc. (NASDAQ: AKBA), its last 5-days average volume was 3.3 million, which is a drop from its year-to-date volume of 4.38 million. As of the previous 9 days, the stock’s Stochastic %D was 20.93%. Additionally, its Average True Range was 0.15.
During the past 100 days, Akebia Therapeutics Inc.’s (AKBA) raw stochastic average was set at 26.73%, which indicates a significant increase from 16.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.17% in the past 14 days, which was lower than the 84.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5964, while its 200-day Moving Average is $1.3159. However, in the short run, Akebia Therapeutics Inc.’s stock first resistance to watch stands at $1.3900. Second resistance stands at $1.4200. The third major resistance level sits at $1.4600. If the price goes on to break the first support level at $1.3200, it is likely to go to the next support level at $1.2800. Should the price break the second support level, the third support level stands at $1.2500.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Key Stats
The company with the Market Capitalisation of 284.74 million has total of 209,372K Shares Outstanding. Its annual sales at the moment are 194,620 K in contrast with the sum of -51,930 K annual income. Company’s last quarter sales were recorded 56,070 K and last quarter income was -50 K.
